54 completed, 31 recruiting, 23 active not recruiting, 22 terminated. 87 Phase 2, 59 Phase 1, 9 Phase 3, 7 Early Phase 1, 7 Not applicable.
Follow Clear Cell Renal Cell Carcinoma: new trials by email Literature Review of Clear Cell Renal Cell Carcinoma trials Research Report on Clear Cell Renal Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2027-05-17 | 2026-10-21 |
| A Study of CA9-Targeted CAR Macrophage Therapy in Advanced Clear Cell Renal Cell Carcinoma CM-BA-9 - Clear Cell Renal Cell Carcinoma | Early Phase 1 | Not yet recruiting | Liangyou Gu | 6 | 2026-11-01 | 2026-10-08 |
| 68Ga- and 18F-CAIX PET Imaging Study 68Ga-CAIX PET/CT, 18F-CAIX - Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Early Phase 1 | Not yet recruiting | Peking University First Hospital | 100 | 2026-10-01 | 2026-10-15 |
| CAIX-targeted PET/CT in Solid Tumors 68Ga-CAIX - Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma | Not applicable | Recruiting | Zhongnan Hospital | 100 | 2026-09-21 | 2026-10-13 |
| Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer(FASTIL-Renal01) Cyclophosphamid, Fludarabine, Interleukin 2 subcutaneous injection - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | Hangzhou Huasai Biomedicine Co., Ltd. | 15 | 2026-08-23 | 2026-10-14 |
| Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery Biospecimen Collection, Clostridium butyricum CBM588 Strain, Computed Tomography - Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 62 | 2026-07-08 | 2026-10-19 |
| A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma PD-32766D (a Copper-64 [64Cu] labeled peptide), PD-32766T (an Actinium-225 [225Ac] labeled peptide) - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | PeptiDream Inc. | 60 | 2026-07-07 | 2026-09-18 |
| Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma Cyclophosphamide, Fludarabine, LNK001 - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 40 | 2026-07-02 | 2026-10-09 |
| Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT) - Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma | Phase 2 | Recruiting | Kelly Fitzgerald, MD | 20 | 2026-06-10 | 2026-07-27 |
| Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma TQB2450 + Anlotinib - Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | RenJi Hospital | 33 | 2026-05-31 | 2026-05-22 |
| Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC XL092, Nivolumab - Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Recruiting | Karie Runcie | 70 | 2026-03-13 | 2026-09-22 |
| An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma SLC-3010 + Axitinib, Axitinib - Clear Cell Renal Cell Carcinoma, Neoplasms | Phase 2 | Recruiting | Yonsei University | 78 | 2026-03-01 | 2026-03-13 |
| Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study Cabozantinib, Nivolumab - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 16 | 2026-02-12 | 2026-08-11 |
| Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer PF-08634404, Ipilimumab, Axitinib - Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Pfizer | 224 | 2026-02-10 | 2026-10-08 |
| Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution - Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | University of Oklahoma | 72 | 2026-01-15 | 2026-03-02 |
| Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE) Pembrolizumab, Belzutifan - Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 10 | 2025-12-19 | 2026-08-20 |
| Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma NEO-811 - Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma | Phase 1 | Recruiting | Neomorph, Inc | 30 | 2025-12-19 | 2026-10-05 |
| Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC QL1706 Combined With Lenvatinib - Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 25 | 2025-11-21 | 2026-02-05 |
| Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC) Belzutifan, Active Surveillance - Active Surveillance, Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 78 | 2025-11-17 | 2026-05-22 |
| Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC piflufolastat F 18 - Clear Cell Renal Cell Carcinoma | Phase 2 / Phase 3 | Withdrawn | Lantheus Medical Imaging | 2025-11-01 | 2025-12-10 |
Showing 20 of 153. Sign in to see all of them.
Carcinoma, Renal Cell (153) · Kidney Neoplasms (18) · Neoplasm Metastasis (11) · Carcinoma, Non-Small-Cell Lung (8) · Neoplasms (8) · Melanoma (7) · Clear-cell metastatic renal cell carcinoma (6) · Squamous Cell Carcinoma of Head and Neck (6) · Colorectal Neoplasms (5) · Triple Negative Breast Neoplasms (5) · Carcinoma (4) · Hodgkin Disease (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Leukemia, Myeloid, Acute (4) · Lymphoma, Non-Hodgkin (4)
Female Urogenital Diseases (153) · Female Urogenital Diseases and Pregnancy Complications (153) · Male Urogenital Diseases (153) · Neoplasms by Histologic Type (153) · Urogenital Diseases (153) · Adenocarcinoma (152) · Neoplasms by Site (152) · Neoplasms, Glandular and Epithelial (152) · Urologic Diseases (152) · Kidney Diseases (151) · Urogenital Neoplasms (151) · Urologic Neoplasms (150) · Carcinoma (149) · Neoplasms (145) · Kidney Neoplasms (135)
Nivolumab (19) · Axitinib (13) · Bevacizumab (11) · Magnetic Resonance Spectroscopy (10) · cabozantinib (10) · pembrolizumab (10) · Sorafenib (9) · Ipilimumab (8) · Sunitinib (8) · Specimen Handling (7) · pazopanib (7) · Biopsy (5) · CTLA-4 Antigen (5) · Cyclophosphamide (5) · Disulfides (5)
National Cancer Institute (NCI) (27) · M.D. Anderson Cancer Center (9) · Peking Union Medical College Hospital (7) · Telix Pharmaceuticals (Innovations) Pty Limited (5) · City of Hope Medical Center (4) · Case Comprehensive Cancer Center (3) · Fred Hutchinson Cancer Center (3) · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (3) · Calithera Biosciences, Inc (2) · Children's Oncology Group (2) · Dana-Farber Cancer Institute (2) · Jonsson Comprehensive Cancer Center (2) · MacroGenics (2) · NiKang Therapeutics, Inc. (2) · Peking University First Hospital (2)
United States (109) · China (25) · Australia (9) · Canada (9) · France (8) · Spain (7) · South Korea (6) · Belgium (5) · Germany (5) · Italy (5) · United Kingdom (5) · Netherlands (3) · New Zealand (3) · Portugal (3) · Puerto Rico (3)
Brenda Sandmaier (3) · Brian Rini (3) · Eric Jonasch, MD (3) · Li Huo, MD (3) · Eric Jonasch (2) · Glenn Liu (2) · Padmanee Sharma (2) · Saby George (2) · Sumanta K Pal (2) · Walter Stadler (2) · Adanma Anji Ayanambakkam Attanathi (1) · Adanma Ayanambakkam, MD (1) · Ajjai Alva, M.D. (1)
PMID 32499241, PMID 37146227, PMID 17395103, PMID 18272024, PMID 20956472, PMID 22259028, PMID 24474568, PMID 25532471, PMID 25900027, PMID 26077237, PMID 26969090, PMID 27634566, PMID 28278333, PMID 28549224, PMID 28945839, PMID 29257710, PMID 29550566, PMID 31371341, PMID 31399500, PMID 31654285, PMID 31703971, PMID 32915679, PMID 32925563, PMID 33305087, PMID 33507454, PMID 33604999, PMID 33888901, PMID 34283029, PMID 34405965, PMID 34480522, PMID 34737281, PMID 34783716, PMID 35031545, PMID 35228755, PMID 35304832, PMID 35383907, PMID 35507017, PMID 35576438, PMID 36464584, PMID 36536472, PMID 36600099, PMID 36848607, PMID 37246998, PMID 37433436, PMID 38008031, PMID 38302476, PMID 38396300, PMID 38531002, PMID 38896853, PMID 38920407
P30CA033572 (4), U10CA180821 (4), P01CA018029 (3), P30CA015704 (3), P30CA016672 (3), U01CA062491 (3), U01CA070095 (3), U10CA021115 (3), U10CA180820 (3), N01CM62201 (2), N01CM62202 (2), N01CM62209 (2), P30CA014520 (2), U10CA031946 (2), UM1CA186689 (2)